Activating kinase fusions have recently been described as early oncogenic events that are mutually exclusive with HRAS and BRAF mutations in Spitz tumors. Here, we report a series of 32 Spitz tumors with ALK fusions (6 Spitz nevi, 22 atypical Spitz tumors, and 4 spitzoid melanomas) in patients ranging from 5 months to 64 years (median = 12 y) of age. The tumors typically presented as exophytic papules on the extremities and were occasionally darkly pigmented. In addition to ALK fusions previously described in other tumor types (NPM1-ALK, TPR-ALK), we identified 2 novel ALK fusions (CLIP1-ALK and GTF3C2-ALK) in our cohort of Spitz tumors. Array comparative genomic hybridization of 19 of these tumors demonstrated a high frequency of chromosome 2 aberrations (where ALK resides, 63%) and chromosome 1p loss in 37% of the cases. Spitz tumors with ALK fusions demonstrated unique histopathologic features. Clefts and small vesicle-like spaces were arrayed between plump spindled melanocytes with fibrillar cytoplasm and enlarged nuclei. These melanocytes were typically arrayed in elongated and fusiform nests with radial orientation. The tumors often had extension into the dermis or subcutis with a wedge-shaped or bulbous lower border (45% and 17%, respectively). An infiltrative growth pattern was often present at the periphery of the tumor and was highlighted by ALK immunohistochemistry. In conclusion, Spitz tumors with ALK rearrangement show distinct histopathologic features that should aid in improving classification of these diagnostically challenging tumors.
S pitz tumors are a subgroup of melanocytic neoplasms with distinctive histopathologic features such as increased cell size and epithelioid or spindled morphology. They are more common in children and adolescents but can occur at all ages. The histopathologic diagnosis of Spitz tumors is notoriously difficult. Although polar examples can be reliably recognized histopathologically, there are many intermediate-grade lesions in which there is a small but real risk of widespread metastasis. Cases on the benign end of the spectrum with no overlapping morphologic features with melanoma are designated as Spitz nevi, whereas cases with unequivocal features of melanoma are designated as spitzoid melanomas. Borderline cases that show overlapping features of Spitz nevus and melanoma have been termed atypical Spitz tumors.
The genetic landscape of Spitz tumors is unfolding, and the differences compared with other categories of melanocytic neoplasms are emerging rapidly. 1 Spitz tumors generally have no mutations in BRAF, NRAS, or KIT, the most commonly activated oncogenes in melanocytic neoplasms with an intraepithelial component, nor mutations in GNAQ or GNA11, which are primarily found in melanocytic neoplasms without epithelial involvement such as blue nevi and related lesions, melanocytomas, and uveal melanomas. 1 One notable exception is the setting of biallelic loss of BAP1, which, in the presence of a BRAF V600E mutation, leads to a distinctive neoplasm with large epithelioid melanocytes reminiscent of Spitz nevus. 2 In contrast to classical Spitz nevi, the neoplasms with BRAF V600E mutations and loss of BAP1 lack the epidermal hyperplasia typical of Spitz nevi, and their epithelioid melanocytes do not usually form junctional nests. 2, 3 Previous studies revealed that approximately 20% of Spitz nevi harbor activating mutations of HRAS, often accompanied by gain of the mutant HRAS allele by copy number increases of the entire short arm of chromosome 11. 4 Spitz nevi with these genetic alterations display distinctive features, frequently presenting as mostly dermal-based lesions with a horizontal rather than vertical orientation, often with marked desmoplasia. 4, 5 Recently, we reported that Spitz tumors without mutations in HRAS or BRAF frequently have genomic rearrangements that lead to fusions involving the threonine kinase BRAF (in its wild-type form) or the receptor tyrosine kinases ALK, ROS1, NTRK1, and RET. 6, 7 The fusion kinases are formed by intrachromosomal or interchromosomal rearrangements that result in chimeric genes in which the 3 0 portion of the kinase gene is linked to the 5 0 portion of another gene to give rise to an in-frame mRNA transcript that encodes a chimeric protein with a constitutively activated kinase. The expression of the fusion transcript is driven by the promoter of the 5 0 partner, decoupling the regulation of expression of the fusion kinase from regulation of the corresponding wild-type kinase. Some of the kinases, such as ALK, ROS1, and RET, are not expressed in most adult cells including melanocytes, and the expression of the activated kinase is considered a pivotal oncogenic event in multiple different tumor types such as anaplastic large cell lymphoma (ALK), inflammatory myofibroblastic tumor (ALK), non-small cell lung cancer (ALK, ROS1, RET), 8 and thyroid cancer (RET, NTRK1). 9, 10 Although there is overlap in the 5 0 partners found in Spitz tumors with those found in other neoplasms, multiple novel 5 0 fusion partners have been identified in Spitz tumors. 6, 7 Kinase fusions in Spitz tumors were found throughout the spectrum of the disease from unequivocally benign Spitz nevi to spitzoid melanomas, indicating that the fusions represent initiating oncogenic alterations, similar to activating mutations in BRAF, NRAS, GNAQ, and GNA11, which are also found in benign nevi.
The findings point to significant genetic diversity in Spitz tumors with a range of different oncogenic driver genes, which themselves are subject to additional variation depending on the 5 0 partner to which they are fused, in contrast to conventional nevi in which an activating BRAF mutation is the oncogenic driver in B90% of cases. 11, 12 Spitz tumors are thus highly genetically heterogenous. This indicates that part of the difficulty in developing accurate and reproducible diagnostic and prognostic parameters for Spitz tumors may be because of their genetic heterogeneity. Spitz tumors with HRAS mutation or BRAF mutation with concomitant loss of BAP1 have unique characteristics. Here we describe the morphologic and genetic features of Spitz tumors with ALK fusions as another possibly distinct subset with characteristic histopathologic features.
MATERIALS AND METHODS

Case Selection
Spitz tumors with ALK fusion were identified during the diagnostic workup of cases reviewed at the Dermatopathology Section of the University of California, San Francisco and from Department of Biopathology at the Centre Le´on Be´rard in Lyon, France. The study was approved by the Committee on Human Research and was conducted according to the Declaration of Helsinki.
Criteria that prompted the suspicion of an ALK rearrangement were morphologic features identified in the index cases in the initial discovery cohort 7 or copy number transitions involving the ALK locus identified by comparative genomic hybridization (CGH) for clinical purposes. ALK rearrangements were confirmed by fluorescence in situ hybridization (FISH), next-generation sequencing including the ALK coding region and intron 19, and/or immunohistochemistry using antibodies directed at the kinase domain of ALK (UCSF: rabbit polyclonal, 1:200, Invitrogen 18-0266 [Life Technologies, Grand Island, NY], Lyon: clone 5A4, 1:100, Leica Microsystems PA0306 [Leica Microsystems, Buffalo Grove, IL]). The histopathologic features were assessed by 2 pathologists (I.Y. and A.F.).
DNA Extraction
Routinely sections were used to guide microdissection. Small amounts of tumor were obtained from 10 to 20 unstained 8 to 20 mm formalin-fixed paraffinembedded (FFPE) sections. DNA extraction was performed using deparaffinization solution (Qiagen #19093, Sussex, UK) and the QIAamp DNA FFPE Tissue Kit (Qiagen #56404) or as described previously. 13 
Array CGH
Array CGH was carried out with 1 to 1.5 mg of genomic DNA on Agilent 4Â 180K microarrays (Agilent, Santa Clara, CA) according to the manufacturer's instructions. Commercially available normal human DNA (Promega #G1471 or #G1521, WI) was used as a reference. Scanned images were processed using Agilent Feature Extraction software. Analysis was performed with Nexus Copy Number Software version 7.0 (Biodiscovery, El Segundo, CA). 
Fluorescence In Situ Hybridization
Targeted DNA Sequencing
For each tissue, 200 ng of DNA was prepared for sequencing using the NuGen Ovation (12 samples, p/n 0331-32, San Carlos, CA) library preparation kits following the manufacturer's instructions. Capture was performed using custom Nimblegen SeqCap EZ Choice Libraries (p/n 06588786001, Madison, WI) (Table S1 for baits, Supplemental Digital Content 1, http://links. lww.com/PAS/A254). Case 19 was sequenced with 15 indel realignment, recalibration, and variant calling were performed using the Genome Analysis Tool-Kit and Unified Genotyper. 16 Structural rearrangements were called using CREST on informative reads (those with soft-clipping and discordant mate-pairs). 17 The target genes were curated to comprise common cancer genes with particular relevance to melanoma. For all sequenced cases, the targeted regions included the exons of ALK, BRAF, NRAS, HRAS, KRAS, GNAQ, GNA11, and KIT and intron 19 of ALK.
RESULTS
Clinical Findings
A total of 32 cases were included in this study, and their clinical features are summarized in Table 1 . The median age of the patients was 12 years with a range from 5 months to 64 years. There was a predominance of female over male individuals (21 and 11, binomial exact test, P = 0.03). Eighteen (56%) lesions arose on the extremities, 8 (25%) on the trunk, and 6 (19%) on the head and neck region. Many of the tumors were clinically amelanotic (n = 12) or vascular appearing (n = 3), and the clinical differential diagnosis included keloid, molluscum contagiosum, basal cell carcinoma, and pyogenic granuloma (Fig. 1A) . Occasionally, pigmentation was noted on clinical examination (n = 5), and some tumors were black in color (Fig. 1B) . Seven of the tumors were 1 cm in size or larger. The final histopathologic diagnosis was Spitz nevus in 6 (19%) cases, atypical Spitz tumor in 22 cases (69%), and spitzoid melanoma in 4 cases (12%). Spitzoid melanomas were distinguished from atypical Spitz tumors by histopathologic features including increased nuclear pleomorphism, the presence of epidermal consumption, lack of maturation, nodularity at the base of the lesion, and deep mitoses. Sentinel node biopsy was negative in all 3 cases in which it was performed. Clinical follow-up was available for 20 patients and ranged from 3 to 40 months (median 9 mo). No patient had a recurrence.
Genetic Findings
The FISH analyses (n = 17) showed 3 different patterns. A single hybridization signal of the probe targeting the kinase domain side of the breakpoint with a loss of the other signal was seen in 3 cases ( Fig. 2A) . This pattern is expected to occur in rearrangements resulting from deletions such as the one that produces the DCTN1-ALK fusion, as well as other unbalanced rearrangements. Split signals were observed in 12 cases ( Fig. 2B ) and are compatible with rearrangements resulting from a reciprocal translocation. Amplification of ALK by FISH (>5 ALK signals/cell) was found in 2 cases (Fig. 2C ).
Array CGH was performed for 19 cases (Fig. 3 ). Five cases (26%) had no detectable copy number aberration. Three cases (16%) demonstrated nearly identical interstitial deletions on the short arm of chromosome 2 (< 0.4 Mbp between start and end sites of the 3 deletions), suggesting a DCTN1-ALK fusion (cases 9, 25, 27). Copy number on chromosome 2 (on which ALK resides) was aberrant in most cases (n = 12, 63%), with 8 of these cases demonstrating copy number aberrations on other chromosomes as well. Seven (37%) cases demonstrated loss on chromosome 1p.
ALK copy number status was assessed by either CGH or FISH for 28 cases. Gain of ALK was observed in 1 (4%) and amplification was observed in 3 (11%) cases in which amplification was defined as log 2 copy number ratio >1.5 (CGH) or >5 signals/cell (FISH) ( Table 1) . Copy number transitions within ALK with relative gain of the 3 0 end (encoding the kinase domain) were present in 8 (29%) cases.
In 4 cases, an activating ALK fusion was identified by targeted sequencing. The fusion partners of ALK identified by sequencing were NPM1, TPR, GTF3C2, and CLIP1 ( Table 2) . NPM1-ALK arose from reciprocal translocation, with fusion junctions for both NPM1-ALK and ALK-NPM1 identified. The other ALK fusions did not arise from reciprocal translocation. In case 11, a GTF3C2-ALK fusion with the 5 0 untranslated region of GTF3C2 fused to exon 18 of ALK was identified (Fig. 4) . The predicted fusion transcript would utilize a cryptic translation start site within exon 18 to express the kinase domain of ALK. FISH demonstrated multiple signals (>5/cell) corresponding to the 3 0 end of ALK scattered throughout the nucleus (Fig. 4B) . By CGH, the B2 Mbp region between GTF3C2 and ALK was amplified (log 2ratio >1.5), consistent with double minute formation followed by amplification (Fig. 4C) . Expression of the kinase domain of ALK was confirmed by immunohistochemistry. None of the cases with ALK fusions that underwent targeted sequencing had oncogenic mutations in BRAF, NRAS, HRAS, or KIT or any other oncogenes.
Histopathologic Findings
The histopathologic features of the ALK-fused tumors differed from those of classical Spitz nevi and are summarized in Table 3 . The median tumor thickness was 2.7 mm (range 0.75 to 7.1 mm), and 5 tumors (16%) were ulcerated. Most lesions (78%) were compound in nature, with both an epidermal and a dermal component. Of the 29 cases in which the base of the tumor was sampled, about a third (38%) demonstrated a flat base, with a majority having a wedge-shaped or bulbous (45 and 17%, respectively) base. Most tumors were exophytic with epidermal hyperplasia. Rarely, consumption of the epidermis (16%) 18 was observed. Kamino bodies were also infrequent (13%). The majority of cases (91%) showed a fascicular growth pattern with melanocytes streaming in large confluent nests or sheets often oriented in a radial pattern, converging toward the base of the tumor. Large nests were often present within an edematous papillary dermis with thinning of the overlying epidermis. Most lesions were amelanotic, but focal pigmentation was present in a quarter of cases. The majority showed a pronounced infiltrative growth pattern with deep dermal invasion. Select cases that highlight these architectural features are presented in Figure 5 .
ALK immunohistochemistry was strongly and homogenously positive in 28 of 29 cases analyzed. The remaining case demonstrated intense punctate cytoplasmic staining. The pronounced infiltrative pattern is best appreciated with ALK immunohistochemistry (Fig. 6) . In several cases, small clusters of ALK-positive cells were seen at considerable distance from the main tumor, often with a distinctive growth pattern with narrow, pseudotubular strands at the periphery of the tumor (Fig. 6A) . Invasion of adnexal structures was noted in a majority of the cases, with melanocytes observed within arrector pili, eccrine ducts, and follicular epithelium (Fig. 6B ). Most of the tumors demonstrated fusiform to polygonal melanocytes with clefts or small vesicle-like spaces separating neighboring cells (Fig. 7) . Their cytoplasm was amphophilic with a fibrillar quality. In many cases the melanocytes had enlarged nuclei and prominent nucleoli (Fig. 7B) . When pigment was noted in melanocytes, it had a coarsely granular quality (Fig. 7B) . Multinucleated melanocytes were present in over one third of cases. Dermal mitoses were not uncommon, observed in almost half (47%) the tumors.
DISCUSSION
The term Spitz tumor is used to describe melanocytic tumors with a predominance of large epithelioid or spindled melanocytes across a spectrum from benign to malignant. 1 These tumors are often diagnostically challenging because they display features associated with melanoma such as large melanocytes with abundant cytoplasm and large nuclei, mitotic figures, and deep dermal involvement. Whereas they commonly involve local lymph nodes, distant metastasis is infrequent. 19, 20 The development of distinct diagnostic criteria for Spitz nevi, separate from those used for common or conventional nevi, greatly improved the accuracy of classification of these tumors. Even with the recognition that Spitz tumors have unique histopathologic features, there is often disagreement among expert dermatopathologists as to their biological potential. 21, 22 The genetic diversity of Spitz tumors may explain the difficulty in developing reliable and reproducible diagnostic criteria for these tumors. ALK fusions are estimated to be present in B8% of Spitz nevi, B5% of atypical Spitz tumors, and B1% of spitzoid melanomas. 7 In this study, we present Spitz tumors with ALK fusions as a distinct subset of Spitz tumors that can be distinguished by genetic features, immunohistochemistry, and histopathology. The age distribution of our patients was broad (5 mo to 64 y), but the majority of tumors occurred in children, similar to what has been previously observed for Spitz nevi and atypical Spitz tumors. None of the patients' tumors recurred, including the 4 patients with spitzoid melanoma who were each followed for >1 year. Although no Spitz tumors with ALK fusions are yet reported to have widely disseminated, it is important to note that kinase inhibitors targeting ALK are approved for clinical use in other cancers driven by these fusions. The ALK-fused tumors in our study demonstrated some distinctive histopathologic features. We found that ALK-fused tumors were often exophytic and composed of large nests of fusiform melanocytes arranged in elongated and radially vertically oriented nests, similar to prior studies. 7, 23 ALK-fused tumors often demonstrated a wedge-shaped or bulbous base and adnexal extension and a markedly infiltrative growth pattern at the lateral and deep periphery of the tumors, best appreciated by ALK immunohistochemistry. A minority of the tumors contained melanocytes with coarsely granular pigment, and melanocytes with dusty melanin pigmentation (socalled pulverocytes) that have been noted in spitzoid melanomas were not present. 24 As in other neoplasms with ALK rearrangements, ALK immunohistochemistry with an antibody against the kinase domain of ALK accurately reflected the genetic findings. These features were present in tumors ranging from benign to malignant.
Our study expands the range of ALK fusions documented in Spitz tumors. Previous studies identified DCTN1 and TPM3 as recurrent N-terminal fusion partners of ALK in Spitz tumors. 7, 23 In the 4 cases we sequenced, we identified ALK fusions not previously described in Spitz tumors. An NPM1-ALK fusion resulted from a t(2;5) translocation; this translocation is found in a majority of anaplastic large cell lymphomas. 25 A similar TPR-ALK fusion to that which we identified was recently described in lung adenocarcinoma. 26 The identification of a CLIP1-ALK fusion supports the hypothesis that the N-terminal partners of kinase fusions may be interchangeable within Spitz tumors as CLIP1 also partners with ROS1 in Spitz tumors. 7 GTF3C2, a subunit of transcription factor IIIC, has not been previously reported to participate in oncogenic fusions. The GTF3C2-ALK fusion we identified appeared to be the result of double minute formation. Copy number aberrations on chromosome 2 (where ALK is located) were present in most of the tumors, and this finding is uncommon in prior CGH studies of Spitz nevi and tumors. [27] [28] [29] [30] Seven (37%) cases demonstrated loss on chromosome 1p, an aberration not previously reported to occur at significant frequency in Spitz nevi, or atypical Spitz tumors, or melanoma.
Whereas ours is the largest cohort of ALK-fused Spitz tumors assembled to date, additional studies are necessary to refine these criteria and determine whether the biological behavior of these lesions is different from other emerging subtypes of Spitz tumors. If confirmed, dividing Spitz tumors into subtypes defined by a combination of genetic, histopathologic, and clinical features is likely to improve the accuracy of diagnosing these lesions in the future.
